National Healthcare Administration: Setting a Certain Price Stabilization Period for High-Level Innovative Drugs
Gloomy Times, July 31st | Wang Xiaoning, Director of the Pharmaceutical Pricing and Procurement Department of the National Healthcare Administration, stated that we support high-level innovative dru
Gloomy Times, July 31st | Wang Xiaoning, Director of the Pharmaceutical Pricing and Procurement Department of the National Healthcare Administration, stated that we support high-level innovative drugs in achieving fair returns commensurate with their high investment and risk at the initial listing stage. In essence, this means a certain price level that is quite satisfactory. Moreover, for high-level innovative drugs, we set a certain price stabilization period. Secondly, from the online filing process aspect, we provide positive support, including adopting a one-province acceptance model for all regions to facilitate the rapid promotion of new drugs into clinical trials.